Bitopertin
Bitopertin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against sodium- and chloride-dependent glycine transporter 1. In addition, it is known to target sodium- and chloride-dependent glycine transporter 2.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 2 | 6 | — | — | 9 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 1 | — | — | — | 1 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 12 | — | — | — | — | 12 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BITOPERTIN |
| INN | bitopertin |
| Description | Bitopertin (developmental code names RG1678; RO-4917838) is a glycine reuptake inhibitor which was under development by Roche as an adjunct to antipsychotics for the treatment of persistent negative symptoms or suboptimally controlled positive symptoms associated with schizophrenia. Research into this indication has been largely halted as a result of disappointing trial results.
|
| Classification | Small molecule |
| Drug class | glycine transporter/reuptake inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 845614-11-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1171829 |
| ChEBI ID | — |
| PubChem CID | 24946690 |
| DrugBank | DB12426 |
| UNII ID | Q8L6AN59YY (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A9
SLC6A9
Organism
Homo sapiens
Gene name
SLC6A9
Gene synonyms
NCBI Gene ID
Protein name
sodium- and chloride-dependent glycine transporter 1
Protein synonyms
glyT-1, solute carrier family 6 (neurotransmitter transporter, glycine), member 9, Solute carrier family 6 member 9
Uniprot ID
Mouse ortholog
Slc6a9 (14664)
sodium- and chloride-dependent glycine transporter 1 (P28571)
Alternate
SLC6A5
SLC6A5
Organism
Homo sapiens
Gene name
SLC6A5
Gene synonyms
GLYT2, NET1
NCBI Gene ID
Protein name
sodium- and chloride-dependent glycine transporter 2
Protein synonyms
norepinephrine transporter 1, solute carrier family 6 (neurotransmitter transporter, glycine), member 5, Solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a5 (104245)
sodium- and chloride-dependent glycine transporter 2 (Q761V0)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 233 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more